Pharmacological advancements are pivotal in improving the management of movement disorders. This track will focus on the latest drug developments, treatment regimens, and the role of pharmacogenomics in optimizing therapy for Parkinson’s, Huntington’s, and other neurodegenerative diseases.
Track 21-1: New Medications for Parkinson’s Disease
Track 21-2: Novel Drug Delivery Systems
Track 21-3: Pharmacogenomics and Personalized Treatment
Track 21-4: Emerging Pharmacological Therapies for Movement Disorders
Track 21-5: Managing Drug Side Effects and Interactions
This track will provide updates on the evolving pharmacological landscape and its potential to improve clinical outcomes for individuals with movement disorders.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
